BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38458097)

  • 1. Meropenem versus piperacillin-tazobactam for the treatment of pancreatic necrosis.
    Racketa S; Gandhi K; Lambie M
    Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116209. PubMed ID: 38458097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
    JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day.
    Kobayashi R; Sano H; Matsushima S; Hori D; Yanagi M; Kodama K; Suzuki D; Kobayashi K
    Int J Hematol; 2021 Mar; 113(3):430-435. PubMed ID: 33170417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
    Ide N; Sato S; Sawaguchi K
    Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
    Chen AY; Deng CY; Calvachi-Prieto P; Armengol de la Hoz MÁ; Khazi-Syed A; Chen C; Scurlock C; Becker CD; Johnson AEW; Celi LA; Dagan A
    Chest; 2023 Aug; 164(2):355-368. PubMed ID: 37040818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
    Aslan AT; Pashayev T; Dağ O; Akova M
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superinfection rate among the patients treated with carbapenem versus piperacillin/tazobactam: Retrospective observational study.
    Al Muqati H; Al Turaiki A; Al Dhahri F; Al Enazi H; Althemery A
    J Infect Public Health; 2021 Mar; 14(3):306-310. PubMed ID: 33618274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
    JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial.
    Hardy M; Harris PNA; Paterson DL; Chatfield MD; Mo Y;
    Clin Infect Dis; 2024 Jun; 78(6):1482-1489. PubMed ID: 38306577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
    McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic Guidelines for Critically Ill Patients in Nigeria.
    Oladele RO; Ettu AO; Medugu N; Habib A; Egbagbe E; Osinaike T; Makanjuola OB; Ogunbosi B; Irowa OO; Ejembi J; Uwaezuoke NS; Adeleke G; Mutiu B; Ogunsola F; Rotimi V
    West Afr J Med; 2023 Sep; 40(9):962-972. PubMed ID: 37768104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Forde BM; Harris P; Shirin T; Habib ZH; Flora MS; Roberts JA
    J Antimicrob Chemother; 2022 Aug; 77(9):2448-2455. PubMed ID: 35724128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
    Zhang W; Yan CY; Li SR; Fan TT; Cao SS; Cui B; Li MY; Fan BY; Ji B; Wang L; Cui F; Cui J; Wang L; Guan Y; Wang JW
    Front Cell Infect Microbiol; 2023; 13():1093842. PubMed ID: 37207190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital.
    Komatsu T; Inagaki R; Azuma S; Mochida S; Sato Y; Seto Y; Nihonyanagi S; Hoshiyama T; Wada T; Takayama Y; Atsuda K
    J Infect Chemother; 2022 Jul; 28(7):884-889. PubMed ID: 35331613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.